Background: Degos disease or malignant atrophic papulosis is a rare occlusive vasculopathic disease characterized by pathognomonic cutaneous lesions and frequently fatal systemic involvement. The etiology of malignant atrophic papulosis remains unclear, and there is currently no effective treatment for malignant atrophic papulosis. Several chemokines can potentiate and expand the platelet response to increase thrombus formation. Among these chemokines, this study examined the expression of stromal cell-derived factor (SDF)-1/CXCL12, which is secreted by bone-marrow stromal and endothelial cells, activates megakaryocyte precursors, and costimulates platelet activation.

Objective: We sought to investigate and compare the expression of SDF-1/CXCL12 in tissue sections taken from 2 patients with Degos disease, 2 patients with other vaso-occlusive diseases, and 2 healthy control subjects.

Methods: Immunohistochemical staining involving antibodies to SDF-1/CXCL12 was performed on 3 skin biopsy specimens taken from 2 patients with Degos disease, 1 from a patient with antiphospholipid syndrome, 1 from a patient with cryoglobulinemia, and 2 from healthy control subjects.

Results: Strong SDF-1/CXCL12 staining was observed in the infiltrating inflammatory cells in the perivascular, intravascular, and perineural areas in tissue samples from patients with Degos disease. No staining was observed in samples from patients with antiphospholipid syndrome or cryoglobulinemia or from healthy control subjects.

Limitations: The number of cases available for evaluation was small. The findings were based primarily on the immunohistochemical results and were not confirmed using other techniques.

Conclusions: The intense staining of SDF-1/CXCL12 in lesions attributed to Degos disease, demonstrated for the first time to our knowledge in this study, suggests SDF-1/CXCL12 involvement in the pathogenesis of the disease.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2012.06.031DOI Listing

Publication Analysis

Top Keywords

degos disease
24
malignant atrophic
12
atrophic papulosis
12
patients degos
12
healthy control
12
disease
8
antiphospholipid syndrome
8
cryoglobulinemia healthy
8
staining observed
8
samples patients
8

Similar Publications

Lupus erythematosus and dermatomyositis.

Clin Dermatol

December 2024

Department of Dermatology, Yale School of Medicine, New Haven, CT. Electronic address:

Dr. Irwin Braverman, a luminary in our field of dermatology, united his love of internal medicine with dermatology to pioneer our understanding of the cutaneous manifestations of systemic disease. His meticulous documentation of physical examination findings in his book Skin Signs of Systemic Disease became fundamental to the training of dermatologists worldwide for decades.

View Article and Find Full Text PDF

I-FP-CIT SPECT enables the detection of presynaptic dopaminergic denervation. It allows to differentiate degenerative parkinsonian syndromes from secondary parkinsonian syndromes or essential tremor, and patients with suspected dementia with Lewy bodies from those with other dementia subtypes. The aim of our study was to evaluate the appropriateness of I-FP-CIT SPECT prescriptions, identify prescriber profiles and analyze changes in prescriptions over a decade in the Neurology department of Avicenne University hospital.

View Article and Find Full Text PDF
Article Synopsis
  • * It can resemble other skin disorders but is distinguishable by its unique histopathological features.
  • * Diagnosis may require a biopsy, as seen in a case where a 50-year-old female was confirmed to have DDD despite no family history or abnormal lab tests, highlighting the need for awareness of rare skin conditions in medical evaluations.
View Article and Find Full Text PDF
Article Synopsis
  • Sleep-disordered breathing (SDB) is common in multiple system atrophy (MSA) patients, and the research evaluated the immediate effects and safety of CPAP therapy for treating SDB.
  • In a study of 63 MSA patients, CPAP therapy showed significant improvements such as normalization of apnea-hypopnea index, reduced arousal index, and increased REM sleep, with most patients tolerating the treatment well.
  • Nonresponders to CPAP therapy tended to have more severe motor symptoms, indicating that the therapy is effective primarily in milder cases of motor impairment in MSA patients.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!